United States Patent 11,850,229 (Tasimelteon) Claim Scope, Legal Coverage, and US Patent Landscape
US Patent 11,850,229 claims a circadian-timing administration strategy for tasimelteon (including a beta-blocker management decision) tied to a specific dose (20 mg once daily) and a defined dosing window (about 0.5 to about 1.5 hours before target bedtime). Dependent claims narrow to particular beta-adrenergic receptor antagonists and to patients with Non-24-Hour Sleep-Wake Disorder.
What is US Patent 11,850,229 and what does it claim for tasimelteon dosing?
Core protected concept (Claim 1): a method of administering tasimelteon 20 mg once daily using a conditional beta-adrenergic receptor antagonist (beta-blocker) check and then either (a) administer despite no beta-blocker, or (b) discontinue the beta-adrenergic receptor antagonist before giving tasimelteon, with both scenarios timed to ~0.5 to ~1.5 hours before target bedtime.
Claim 1 scope elements (right-to-use breakdown)
Claim 1 is a classic “improvement” method claim with three required functional components and two timing/dose anchors:
- Act: determine whether the patient is “being treated with a beta-adrenergic receptor antagonist.”
- If not treated: administer 20 mg tasimelteon once daily at a time of about 0.5 to about 1.5 hours before target bedtime.
- If treated: discontinue the beta-adrenergic receptor antagonist before administering 20 mg tasimelteon once daily at the same ~0.5 to ~1.5 hours before target bedtime.
- Conditional logic must be practiced as written: the method is infringed when the clinician (or system implementing the method) follows both the determination and the scenario-specific instruction.
- Specific dosing regimen is anchored: the method is not a general “timing” claim; it is tied to 20 mg once daily.
Practical inference for claim scope: if a regimen deviates materially from dose or timing window, it is outside claim 1. If the clinician identifies beta-blocker use but does not discontinue it, the claim language requires discontinuation “before administering” in the beta-blocker scenario.
“Improvement” language and how it affects coverage
The improvement clause does not broaden the method beyond its enumerated steps. It reinforces that the method’s novelty is in the beta-blocker decision and/or the dosing-timing protocol. The claim remains limited to the described conditional discontinuation logic and dosing window.
What is the dependent claim 2 protected scope for specific beta-adrenergic receptor antagonists?
Claim 2 narrows Claim 1 by restricting the beta-adrenergic receptor antagonist to a set:
- alprenolol
- altenolol
- carvedilol
- metoprolol
- propanolol
Infringement boundary implied by Claim 2
A patient being treated with a beta-blocker not in the enumerated list (for example, propranolol is listed; atenolol is listed as “altenolol” not “atenolol,” so the exact spelling matters) would not satisfy Claim 2 as written. For coverage analysis, Claim 2 is a narrower subset of Claim 1.
Relationship between Claim 1 and Claim 2
- Claim 1 covers “beta-adrenergic receptor antagonist” broadly (as a functional class), without restricting to named agents.
- Claim 2 restricts to five named antagonists. If a competitor’s label-adjacent protocol involves a different beta-blocker, it may still fall under Claim 1 but not Claim 2.
What is the dependent claim 3 protected scope for Non-24-Hour Sleep-Wake Disorder?
Claim 3 narrows Claim 2 by requiring that the patient is suffering from:
- Non-24-Hour Sleep-Wake Disorder
Practical implication
Claim 3 covers the same beta-blocker enumerated subset plus the specific indication. A method applied to other circadian disorders (or to “late sleep phase,” shift-work disorder, insomnia subtypes, etc.) would not meet Claim 3 even if it uses the same dosing window and beta-blocker management approach.
When does the claimed dosing window apply, and how specific is “about one-half hour to about one-and-one-half hours”?
Claim 1 defines timing as:
- “about one-half hour to about one-and-one-half hours before the target bedtime.”
Scope construction considerations for design-around
The claim uses “about,” which typically permits some tolerance around endpoints. The claim still anchors to a bounded interval (not a wide “several hours” window). A competing method that consistently administers outside that range risks avoiding infringement.
“Target bedtime” requirement
The method requires using the patient’s “target bedtime.” Protocols based on a different reference point (for example, fixed clock time not tied to target bedtime, or administration relative to sleep onset estimates not labeled as “target bedtime”) could be argued as nonconforming.
How does the claim handle patients already on beta-adrenergic receptor antagonists?
Claim 1 includes a distinct branch:
- if the patient “is being treated with a beta-adrenergic receptor antagonist,” then discontinuing that therapy before administering tasimelteon.
Coverage implications
- A protocol that instead reduces dose, switches to a different class, continues the beta-blocker through tasimelteon administration, or uses a washout without “discontinuing” (as a discontinuation) would be outside the specific conditional step.
- A “taper” could be considered discontinuation depending on how it is done operationally, but the claim requires that discontinuation occur “before administering” tasimelteon.
What is the US patent landscape around tasimelteon (AAN/Non-24) and method-of-use style claims?
The US patent estate for branded therapeutics like tasimelteon typically clusters into:
- Active ingredient composition and process (earlier priority, often expired or nearing expiry depending on filing history).
- Polymorph/solid form, formulation, and delivery (tablets/capsules, specific excipients, manufacturing).
- Method-of-use and treatment regimen (timing, patient selection criteria, dose range adjustments, comorbid management).
- Regulatory exclusivity-driven protections (not patents but create barriers to generics/biosimilars only to the extent listed with the Orange Book).
For 11,850,229 specifically, the claims are method-of-treatment with an individualized management condition (beta-blocker presence) and a tight dosing-time window.
What this means for infringement strategy
This type of claim tends to be harder for generic “label mirroring” to neutralize because a generic often follows label dosing and indication, but method claims can still be asserted against prescribers, patients, and provider workflows if they practice the method steps (particularly “discontinue before tasimelteon” conditional logic).
What patents are likely to cover tasimelteon’s circadian timing and “before bedtime” regimens?
11,850,229 itself is positioned as a circadian-timing plus comedication discontinuation improvement. In a typical landscape, closely adjacent claims in the same family or related families often include:
- dosing once nightly before bedtime (or in a specific window relative to bedtime),
- indication-limited language for Non-24-Hour Sleep-Wake Disorder,
- dose-specific regimens (including 20 mg),
- regimen modifications tied to comedications affecting melatonin pathways.
How to think about claim adjacency (without inventing numbers)
Even without enumerating specific other US publication numbers here, the commercial risk usually comes from overlapping method claims in the same therapeutic area: a competitor entering tasimelteon would need to assess:
- whether their intended prescribing workflow uses the same timing window,
- whether beta-blocker management is required,
- whether the approach is indication-restricted.
Which companies are at risk, and how do generic entry risks map to method claims like 11,850,229?
A generic manufacturer can typically launch only if it can address:
- patent protection listed for the NDA,
- method-of-use protections asserted via timing and treatment regimen.
Generic entry scenarios for method-of-use claims
- ANDA at launch with carve-out/labeling changes: if the label does not instruct discontinuation of beta-blockers and does not specify the dosing window, infringement exposure can shift away from label-mirroring and toward off-label practice.
- No label change, prescriber follows method: method claims can still create exposure even when the method is not expressly directed by the label, depending on claim construction and the jurisdiction.
- Protocol designed around timing window: if a clinician uses tasimelteon at times consistently outside the ~0.5 to ~1.5 hour window, it may avoid practicing Claim 1.
- Protocol designed around discontinuation: if beta-blocker therapy is not discontinued prior to tasimelteon, Claim 1’s conditional branch can be avoided.
Where exposure concentrates
Exposure concentrates where:
- clinicians treat Non-24-Hour Sleep-Wake Disorder using 20 mg tasimelteon once daily,
- and they implement comedication discontinuation of beta-adrenergic receptor antagonists before dosing,
- and they administer within the defined window.
Does 11,850,229 look like a composition, formulation, or method claim for FDA/Orange Book purposes?
It is a method-of-use claim. In practice, such patents typically appear in the Orange Book tied to:
- the NDA,
- a listed use (indication-specific).
That drives key behavior for ANDA Paragraph IV strategies: the filer must address the listed method patents covering the claimed use.
Operational implication: even if generic formulation patents expire or are invalidated, method patents can still block “practicing the method” if they remain enforceable and listed.
How strong is 11,850,229’s claim position on novelty and enforceability?
Strength analysis for this specific claim type typically hinges on:
- Precision: It has precise dose (20 mg), frequency (once daily), and timing window (~0.5 to ~1.5 hours before bedtime).
- Clinical decision node: It requires a determination about whether the patient is on a beta-adrenergic receptor antagonist, and for that branch, requires discontinuation before dosing.
- Dependent narrowing: Claim 2 and Claim 3 restrict beta antagonists and indication, respectively, reducing breadth but increasing specificity.
In infringement, the strongest points are usually:
- provable patient treatment facts (medication history),
- dosing time documentation,
- and indication.
In validity, typical attack surfaces for such method claims include anticipation/obviousness based on prior clinical protocols and circadian dosing literature. However, a definitive strength rating requires the application’s file history, cited art, and the prosecution record, which are not provided here.
What is the likely enforcement and litigation posture for a method claim with discontinuation language?
Method claims with “discontinuing” language often become fact-intensive. Litigation usually focuses on:
- whether the patient was “being treated” with the beta-adrenergic receptor antagonist at the relevant time,
- whether discontinuation occurred “before administering” tasimelteon,
- and whether the tasimelteon dose and timing window were followed.
These are not purely label-based questions; they are prescribing and treatment-history questions.
Does 11,850,229 create a distinct risk versus other circadian dosing patents?
Yes, because it adds a comedication-management requirement rather than only a dosing-time regimen. A competitor might otherwise copy dosing timing protocols to avoid an earlier “before bedtime” claim. This patent adds an additional conditional step: beta-blocker discontinuation based on the patient’s beta-adrenergic receptor antagonist status.
That creates a separate design-around axis:
- timing,
- and comedication discontinuation.
Key takeaways
- US Patent 11,850,229 protects a conditional tasimelteon 20 mg once-daily dosing method tied to a ~0.5 to ~1.5 hour pre-bedtime window.
- Claim 1 requires determining whether the patient is on a beta-adrenergic receptor antagonist and, if so, discontinuing it before tasimelteon administration.
- Claim 2 narrows the beta-blocker list to alprenolol, altenolol, carvedilol, metoprolol, and propanolol.
- Claim 3 further narrows the indication to Non-24-Hour Sleep-Wake Disorder.
- The practical infringement risk concentrates on clinical workflows that: (i) use 20 mg once-daily tasimelteon, (ii) administer within the specified window, and (iii) discontinue beta-adrenergic antagonists before dosing.
FAQs
1) Does US 11,850,229 cover tasimelteon dosing outside the 0.5 to 1.5 hour window before bedtime?
The claim language requires administering “about one-half hour to about one-and-one-half hours before the target bedtime.” Consistent dosing outside that window avoids Claim 1’s timing limitation.
2) If the patient is on a beta-blocker not listed in Claim 2, is infringement still possible?
Claim 1 covers “beta-adrenergic receptor antagonist” generally, while Claim 2 narrows to five named agents. A non-listed beta-blocker may still satisfy Claim 1.
3) What if the beta-blocker is reduced rather than discontinued?
Claim 1 requires “discontinuing beta-adrenergic receptor antagonist treatment before administering.” A mere reduction without discontinuation does not match the claim’s conditional step.
4) Is the non-24 indication required to infringe Claim 1?
No. Non-24 is only in dependent Claim 3. Claim 1 can apply beyond Non-24 if the method steps are practiced.
5) Can generic or biosimilar entry eliminate this risk?
If the patent remains enforceable, method claims can still create exposure when clinicians practice the claimed method steps, even if the drug itself is generic. Label changes can affect off-label risk depending on jurisdictions and enforcement posture.
References
- U.S. Patent 11,850,229.
